The concept of using bispecific antibodies for cancer therapy by retargeting immune effector cells was developed several years ago. Initial clinical studies were rather disappointing mainly due to low efficacy, severe side effects and the immunogenicity of the bispecific antibodies. The progress in antibody engineering finally led to the generation of new classes of bispecific antibodies lacking these obstacles. In addition, new applications were established, such as pre-targeting strategies in radioimmunotherapy and dual targeting approaches in order to improve binding, selectivity and efficacy.

In this book, the different ways of generating bispecific antibodies are described, with emphasis on recombinant formats. The various applications of bispecific antibodies, e.g. in cellular cancer immunotherapy, radioimmunotherapy and pretargeting strategies are covered, and emerging applications such as dual targeting strategies, which involve the simultaneous inhibition of two targets, are addressed.

<p>Janice M. Reichert: Foreword

Roland Kontermann: Bispecific antibodies: developments and current perspectives
Gerd Moldenhauer: Bispecific antibodies from hybrid hybridoma
Diego Ellerman & Justin Scheer: Generation of bispecific antibodies by chemical conjugation
Christoph Stein, Ingo Schubert & Georg Fey: Trivalent and trispecific antibody derivatives for cancer therapy
Dafne Müller & Roland Kontermann: Diabodies, single-chain diabodies and their derivatives
Patrick Chames & Daniel Baty: Bispecific single domain antibodies
John Löfblom & Fredrik Y. Frejd: Alternative scaffolds as bispecific antibody mimetics
Nico Mertens: Tribodies: building trispecificity by Fab-scFv fusions
Pei Jin & Zhenping Zhu: The design and engineering of IgG-like bispecific antibodies
Edit Tarcsa, Wolfgang Fraunhofer, Tariq Ghayur, Jochen Salfeld & Jijie Gu: Dual-variable-domain immunoglobulin (DVD-Ig^TM) technology: a versatile, novel format for the next generation of dual-targeting biologics
Patrick Koenig & Germaine Fuh: Two-in-one antibodies
Chien-Hsing Chang, Edmund A. Rossi, Robert Sharkey & David M. Goldenberg: The Dock-and-Lock (DNL) approach to novel bispecifc antibodies
Christian Kellner, Matthias Peipp & Thomas Valerius: Effector cell recruitment by bispecific antibodies
Lawrence Lum & Archana Thakur: Bispecific anibodies for arming activated T cells and other effector cells for tumor therapy
Patrick Baeuerle, Gerhard Zugmaier & Dominik Rüttinger: Bispecific T cell engager for cancer therapy
Horst Lindhofer, Jürgen Hess & Peter Ruf: Trifunctional Triomab® antibodies for cancer therapy
Bruno Robert, Christel Larbouret, David Azria, Jean-Pierre Mach & André Pèlegrin: Bispecific antibodies for the retargeting of cytokines
Dirk Nettelbeck: Bispecific antibodies and gene therapy
Archana Parashar, Susmita Sarkar, Advaita Ganguly, Saikiran Sharma & Mavanur R.Suresh: Bispecific antibodies for diagnostic applications. </p>